Clinical Trial

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 13, 2023 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-08.
Trial Details
NCT Number NCT05897138
Lead Sponsor Fujian Cancer Hospital
Conditions Hepatocellular Carcinoma
Enrollment 30 participants
Start Date 2023-08-01
Primary Completion 2025-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2023-06-13